Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OzoParQT: Ozone Treatment for Chemotherapy-Induced Peripheral Neuropathy Paresthesia
2024-517196-20-00Phase 3Authorised
- Sponsor
- Dr. Negrín University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of oxygen + ozone in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Dr. Negrín University Hospital. Primary endpoints: Change from baseline in self-perceived paresthesia at end of follow-up and Change from baseline in EQ-5D-5L quality of life at end of follow-up. Planned start Nov 2024; status: authorised.
02
Drugs
oxygen + ozone
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2024-517196-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517196-20-00.